RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 91 filers reported holding RHYTHM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 500 | -89.6% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 4,800 | +2300.0% | 0.00% | – |
| Q1 2023 | $1 | -92.3% | 200 | -98.0% | 0.00% | -100.0% |
| Q4 2022 | $13 | -100.0% | 9,900 | -54.2% | 0.00% | -83.3% |
| Q3 2022 | $90,000 | +1700.0% | 21,600 | +1076.5% | 0.01% | – |
| Q2 2022 | $5,000 | -76.2% | 1,836 | -21.4% | 0.00% | -100.0% |
| Q1 2022 | $21,000 | -90.6% | 2,336 | -85.2% | 0.00% | -90.9% |
| Q2 2021 | $224,000 | -12.5% | 15,818 | -8.0% | 0.01% | -15.4% |
| Q1 2021 | $256,000 | +71.8% | 17,202 | +81.1% | 0.01% | +85.7% |
| Q4 2020 | $149,000 | +10.4% | 9,500 | -18.1% | 0.01% | -22.2% |
| Q3 2020 | $135,000 | +575.0% | 11,600 | +1060.0% | 0.01% | +800.0% |
| Q2 2020 | $20,000 | – | 1,000 | +150.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 400 | +100.0% | 0.00% | – |
| Q4 2019 | $2,000 | -50.0% | 200 | 0.0% | 0.00% | – |
| Q3 2019 | $4,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |